Sorafenib-induced Pancreatic Pseudocyst in a Patient with Advanced Hepatocellular Carcinoma: a Rare Adverse Event

A 54-year old man diagnosed with advanced hepatocellular carcinoma began treatment with sorafenib. After 3 weeks of treatment, he complained of abdominal pain and nausea. Abdominal sonography showed multiple hepatic lesions only. Serum amylase and lipase levels were 35 U/L and 191 U/L, respectively. The patient was diagnosed with sorafenib-induced acute pancreatitis. After 10 days of discontinuing sorafenib he still complained of nausea and loss of appetite. Esophagogastroduodenoscopy showed a large bulging lesion, which was suspected to cause extrinsic compression on the high body of the gastric anterior wall. Computed tomography scan revealed a cystic lesion, 8.3 cm in size, in the pancreatic tail, suggesting a pancreatic pseudocyst. After the withdrawal of sorafenib, systemic chemotherapy with Adriamycin and cisplatin was administered. Four months after the discontinuation of sorafenib, the size of the pancreatic pseudocyst decreased from 8.3 cm to 3 cm. The patient's symptoms were also relieved.

Oculogyric crisis following single administration of clebopride maleate

@#The oculogyric crisis is a type of acute dystonia characterized by the spasmodic movement of the eyeball, usually upward, and each spasm lasts from seconds to hours. This phenomenon can be caused by the administration of dopaminergic receptor blocking agents. There was a previous report of the oculogyric crisis induced by clebopride, a dopaminergic receptor blocking agent in a patient who took the medicine for several days. We report a 16-year-old female with an oculogyric crisis induced by a single administration of the same drug. Her oculogyric crisis was completely resolved by benzodiazepine